PHVS
SellHot AirPharvaris N.V. · Healthcare · Switzerland · $2.5B · Avg Vol: $36M/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT PHARVARIS N.V.
Read
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative oral bradykinin-B2-receptor antagonists for rare diseases, specifically hereditary angioedema (HAE). The company's competitive edge is derived from its oral drug candidates, which aim to offer convenience and improved patient experience compared to existing injectable therapies. Its success hinges on clinical trial outcomes and regulatory approvals.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 37.0M | — |
| EPS | -1.26 | -3.02 | -2.85 | -3.41 | — | -3.00 | -3.18 | -3.11 | — |
| Shares | 69.9M | 52.3M | 54.4M | 65.2M | -6.7% | 70.2M | — | — | — |
| Debt | 0.5M | 0.3M | 1.0M | 0.9M | 21.2% | 0.8M | — | — | — |
| Equity | 171.5M | 441.3M | 307.7M | 311.7M | 22.0% | — | — | — | — |
| Op CF | -77.2M | -106.9M | -138.0M | -157.5M | — | -178.1M | — | — | — |
| Inv CF | -0.1M | -0.1M | -0.6M | -0.2M | — | — | — | — | — |
| Fin CF | 9.9M | 373.9M | 3.1M | 184.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PHVS | Pharvaris N.V.(you) | $2.5B | 21 | Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 22 | Sell |
| CRSPN.MX | CRISPR Therapeutics AG | $5.6B | 20 | Sell |
| MLTX | MoonLake Immunotherapeutics | $1.3B | 8 | Strong Sell |
| OCS | Oculis Holding AG | $678M | 6 | Strong Sell |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 20 | Sell |
| ACIU | AC Immune SA | $299M | 13 | Strong Sell |
| BANB.SW | Bachem Holding AG | $7.1B | 53 | Hold |
| MOLN.SW | Molecular Partners AG | $172M | 19 | Strong Sell |
| BBZA.DE | BB Biotech AG | $3.1B | 99 | Strong Buy |
Peer medians: ROE 11.1% · P/E 29.9x · Gross margin 60.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.